Diadem Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Later Stage VC
- Investors
-
6
Diadem General Information
Description
Developer of a diagnostic platform designed to predict Alzheimer's disease in advance. The company's platform offers predictions, monitoring, diagnosis, and successful drug development for Alzheimer's disease, enabling patients to get treatment at a cost-effective price.
Contact Information
Website
diademdx.comCorporate Office
- Via Ceresio 7
- Milan
- Italy
Corporate Office
- Via Ceresio 7
- Milan
- Italy
Diadem Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 13-Aug-2026 | Completed | Generating Revenue | |||
| 4. Grant | 07-Sep-2022 | Completed | Generating Revenue | |||
| 3. Later Stage VC | 24-Feb-2022 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series A) | 21-Dec-2018 | $1.7M | $1.7M | Completed | Pre-Clinical Trials | |
| 1. University Spin-Out | 01-Jan-2012 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Diadem Patents
Diadem Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250208143-A1 | P53 fragments as markers for diagnosis and prognosis of neurodegenerative disease states | Pending | 22-Dec-2023 | ||
| US-20260235628-A1 | U-p53 peptides as markers in the rate of progression of cognitive decline to alzheimer's disease | Pending | 08-Jan-2023 | ||
| WO-2024148357-A2 | U-p53 peptides as markers in the rate of progression of cognitive decline to alzheimer's disease | Inactive | 08-Jan-2023 | ||
| WO-2024148357-A3 | U-p53 peptides as markers in the rate of progression of cognitive decline to alzheimer's disease | Inactive | 08-Jan-2023 | ||
| US-20250172555-A1 | Device for detection and prognostic assessment of neurodegenerative disorders | Pending | 02-Aug-2022 | G01N33/54388 |
Diadem Signals
Diadem Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Seed Healthcare | Venture Capital | Minority | ||
| Tech and Biomedical Foundation | Venture Capital | Minority | ||
| National Institute on Aging | Government | |||
| CDP Venture Capital (Rome) | Venture Capital | Minority | ||
| Panakes Partners | Venture Capital | Minority |
Diadem FAQs
-
When was Diadem founded?
Diadem was founded in 2012.
-
Where is Diadem headquartered?
Diadem is headquartered in Milan, Italy.
-
What is the size of Diadem?
Diadem has 10 total employees.
-
What industry is Diadem in?
Diadem’s primary industry is Diagnostic Equipment.
-
Is Diadem a private or public company?
Diadem is a Private company.
-
What is Diadem’s current revenue?
The current revenue for Diadem is .
-
How much funding has Diadem raised over time?
Diadem has raised $21.5M.
-
Who are Diadem’s investors?
Seed Healthcare, Tech and Biomedical Foundation, National Institute on Aging, CDP Venture Capital (Rome), and Panakes Partners are 5 of 6 investors who have invested in Diadem.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process